What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Saúde e medicinaOne-Off10m
Manifold MarketsSem KYCDados de resolução verificadosBem calibradoPrevisão da comunidade atual60-69% 25.7%Líder entre 7 opções
Previsores
15
Tipo de pergunta
multiple choice
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Variação 7d
+0.1 pts
Dados do mercado
Atualizado há 15 horas
Desatualizado15/03/24, 21:29 UTC2/09/27, 06:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWhen will the FDA reclassify BPC-157 to Category 1?
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026? [Polymarket]
Manifold MarketsRegras
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.